Emergent Biolsolutions Inc. recently received a task order from the Biomedical Advanced Research and Development Authority (BARDA) for the development of monoclonal antibody therapeutics for the treatment of viral hemorrhagic fever.
The agreement consists of a 36-month base period of performance with a base task order valued at approximately $7.4 million. If all options are exercised, the total order would be valued up to three years for a total of $30.5 million.
Emergent’s Center for Innovation in Advanced Development and Manufacturing (CIADM) facility will be heavily involved in filling the order. Utilizing monoclonal antibodies provided by Mapp Biopharmaceutical Inc., the company will conduct technology transfer of process materials and information, perform process and analytical method development, and execute small-scale production runs. Emergent will also perform cGMP cell banking, which will lead to cGMP manufacturing of bulk drug substances.
The order will be the fourth BARDA task order under Emergent’s CIADM program.
“Protecting and enhancing life is at the core of Emergent’s mission, and one of the ways by which we are able to fulfill this mission is in partnership with BARDA as it addresses emerging public health threats,” Adam Havey, president of Emergent’s Biodefense Division, said. “Emergent’s CIADM is a great example of a public-private partnership that works towards a shared goal. We look forward to successfully executing this task order in collaboration with all parties involved.”